The results showed that higher SRSF9 expression was consistently correlated to shortened overall survival of glioma patients (Fig. 2A–C), which was further validated by 6 GEO cohorts for GBM patients (Fig. 2D–I). This evidence concerns the gene SRSF9 and central nervous system cancer.